Drug Profile
Research programme: bispecific antibody therapy - MAT Biopharma
Alternative Names: Anti-CD5/anti-CD32 bispecific antibody therapy - MAT Biopharma; Bispecific antibody cancer therapy - MAT BiopharmaLatest Information Update: 23 Feb 2011
Price :
$50
*
At a glance
- Originator MAT Biopharma
- Class Bispecific antibodies
- Mechanism of Action Apoptosis stimulants; CD5 antigen inhibitors; IgG receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia
Most Recent Events
- 23 Feb 2011 Discontinued - Preclinical for Chronic lymphocytic leukaemia in France (Parenteral)
- 13 Jun 2005 Preclinical trials in Chronic lymphocytic leukaemia in France (Injection)